Health ❯ Healthcare ❯ Pharmaceuticals ❯ Cancer Treatment

Pancreatic Cancer

New Oral Drug Nearly Doubles Survival for Treated Metastatic Pancreatic Cancer

Targeting mutant KRAS through cyclophilin A, the pill has been made available under an FDA expanded access pathway pending formal review.

NEJM Study and FDA Access Advance Daraxonrasib for Pancreatic Cancer

FDA Authorizes Early Access to Daraxonrasib for Pancreatic Cancer Patients

Revolution Medicines Drug Nearly Doubles Survival in Phase 3 Pancreatic Cancer Trial